{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T19:22:38Z","timestamp":1773343358996,"version":"3.50.1"},"reference-count":29,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T00:00:00Z","timestamp":1754265600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Gilead Sciences, Inc"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Journal of Medical Economics"],"published-print":{"date-parts":[[2025,12,31]]},"DOI":"10.1080\/13696998.2025.2536422","type":"journal-article","created":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T07:51:38Z","timestamp":1752825098000},"page":"1241-1251","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":5,"title":["Treatment persistence among treatment-experienced people with HIV switching to integrase strand transfer inhibitor\u2013based antiretroviral regimens"],"prefix":"10.1080","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4255-9649","authenticated-orcid":false,"given":"Ching-Yi","family":"Chuo","sequence":"first","affiliation":[{"name":"Gilead Sciences, Inc","place":["Foster City, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8769-9931","authenticated-orcid":false,"given":"Mary J.","family":"Christoph","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc","place":["Foster City, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Woodie","family":"Zachry","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc","place":["Foster City, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8495-8475","authenticated-orcid":false,"given":"Melanie","family":"de Boer","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc","place":["Foster City, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8968-4861","authenticated-orcid":false,"given":"Megan","family":"Chen","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc","place":["Foster City, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cassidy","family":"Trom","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc","place":["Foster City, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2025,8,4]]},"reference":[{"key":"e_1_3_3_2_1","unstructured":"Department of Health and Human Services Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV (2024 edition). 2024 [cited 2025 May 7]. Available from: https:\/\/clinicalinfo.hiv.gov\/sites\/default\/files\/guidelines\/documents\/adult-adolescent-arv\/guidelines-adult-adolescent-arv.pdf."},{"key":"e_1_3_3_3_1","unstructured":"European AIDS Clinical Society (EACS). EACS guidelines 2023 version 12.0. 2023 [cited 2025 May 7]. Available from: https:\/\/www.eacsociety.org\/media\/guidelines-12.0.pdf."},{"key":"e_1_3_3_4_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.22246"},{"key":"e_1_3_3_5_1","unstructured":"Department of Health and Human Services Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV (2017 edition). 2017 [cited 2025 May 7]. Available from: https:\/\/clinicalinfo.hiv.gov\/sites\/default\/files\/guidelines\/archive\/AdultandAdolescentGL003510.pdf."},{"key":"e_1_3_3_6_1","unstructured":"Department of Health and Human Services Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV (2019 edition). 2019 [cited 2025 May 7]. Available from: https:\/\/clinicalinfo.hiv.gov\/sites\/default\/files\/guidelines\/archive\/2019_12_18_AdultandAdolescentGL.pdf."},{"key":"e_1_3_3_7_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e328340feb0"},{"key":"e_1_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.1177\/2325958219867325"},{"key":"e_1_3_3_9_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000000084"},{"key":"e_1_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S207908"},{"key":"e_1_3_3_11_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12981-020-00268-1"},{"key":"e_1_3_3_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10461-023-04208-8"},{"key":"e_1_3_3_13_1","doi-asserted-by":"publisher","DOI":"10.1089\/AID.2020.0286"},{"key":"e_1_3_3_14_1","doi-asserted-by":"publisher","DOI":"10.1080\/17460794.2024.2403246"},{"key":"e_1_3_3_15_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1004325"},{"key":"e_1_3_3_16_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2024.2436288"},{"key":"e_1_3_3_17_1","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2022.2088714"},{"key":"e_1_3_3_18_1","unstructured":"ViiV Healthcare. Cabenuva (cabotegravir extended-release injectable suspension; rilpivirine extended-release injectable suspension) [package insert]. 2022 [cited 2025 May 7]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/212888s005s006lbl.pdf."},{"key":"e_1_3_3_19_1","unstructured":"ViiV Healthcare. Dovato (dolutegravir and lamivudine) [package insert]; 2024 [cited 2025 May 7]. Available from: https:\/\/gskpro.com\/content\/dam\/global\/hcpportal\/en_US\/Prescribing_Information\/Dovato\/pdf\/DOVATO-PI-PIL.PDF."},{"key":"e_1_3_3_20_1","unstructured":"Gilead Sciences. Biktarvy (bictegravir emtricitabine and tenofovir alafenamide) [package insert]. 2018 [cited 2025 May 7]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/210251s000lbl.pdf."},{"key":"e_1_3_3_21_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkab481"},{"key":"e_1_3_3_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.13493"},{"key":"e_1_3_3_23_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkae138"},{"key":"e_1_3_3_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2023.107040"},{"key":"e_1_3_3_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1293.2007.00436.x"},{"key":"e_1_3_3_26_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0171227"},{"key":"e_1_3_3_27_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12981-020-00328-6"},{"key":"e_1_3_3_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.farma.2023.12.005"},{"key":"e_1_3_3_29_1","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.171409"},{"key":"e_1_3_3_30_1","unstructured":"Centers for Disease Control and Prevention. Behavioral and clinical characteristics of persons with diagnosed HIV infection\u2014medical monitoring project United States 2020 Cycle (June 2020\u2013May 2021). HIV Surveillance Special Report 29. 2022 [cited 2025 May 7]. Available from: https:\/\/stacks.cdc.gov\/view\/cdc\/149117."}],"container-title":["Journal of Medical Economics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13696998.2025.2536422","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T10:47:17Z","timestamp":1766400437000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13696998.2025.2536422"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,4]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12,31]]}},"alternative-id":["10.1080\/13696998.2025.2536422"],"URL":"https:\/\/doi.org\/10.1080\/13696998.2025.2536422","relation":{},"ISSN":["1369-6998","1941-837X"],"issn-type":[{"value":"1369-6998","type":"print"},{"value":"1941-837X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,4]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-05-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-11","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-16","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-04","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}